Advanced Search
Contact | Corporate | Help

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Sponsors:
  • Sarah Cannon Research Institute
  • Genentech
  • Sanofi-Aventis
Phases:
  • Phase II
IndicationsAcronym:
  • Non-small Cell Lung Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: Docetaxel, Carboplatin, Bevacizumab, Erlotinib
  • Drug: Docetaxel, Carboplatin
Enrollment:
172

Additional information about NCT00621049.


SourceSolution © 2008-2012